Accelerating Product Development in Global Health
Lead Research Organisation:
Liverpool School of Tropical Medicine
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Publications
Adolfi A
(2018)
Multi-tissue GAL4-mediated gene expression in all Anopheles gambiae life stages using an endogenous polyubiquitin promoter.
in Insect biochemistry and molecular biology
Adolfi A
(2018)
Opening the toolkit for genetic analysis and control of Anopheles mosquito vectors.
in Current opinion in insect science
Adolfi A
(2019)
Functional genetic validation of key genes conferring insecticide resistance in the major African malaria vector, Anopheles gambiae.
in Proceedings of the National Academy of Sciences of the United States of America
Blundell P
(2019)
A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors.
in Methods in molecular biology (Clifton, N.J.)
Blundell PA
(2017)
Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
in The Journal of biological chemistry
Blundell PA
(2019)
Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus.
in Journal of immunology (Baltimore, Md. : 1950)
Blundell PA
(2020)
Choice of Host Cell Line Is Essential for the Functional Glycosylation of the Fc Region of Human IgG1 Inhibitors of Influenza B Viruses.
in Journal of immunology (Baltimore, Md. : 1950)
Ingham V
(2019)
A sensory appendage protein protects malaria vectors from pyrethroids
in Nature
Lloyd KA
(2017)
Glycan-independent binding and internalization of human IgM to FCMR, its cognate cellular receptor.
in Scientific reports
| Title | Rebecca Lennon Exhibition at Dilston Grove. London |
| Description | Preparing material for a video artwork installation. High resolution video footage and recordings were made of mosquitoes feeding to provide material for an abstract and poetic art film that will provide arresting imagery for projection in the converted church gallery. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2019 |
| Impact | The video footage is being prepared for the installation and still images have been provided to the LSTM without copyright to be used for teaching and communication. |
| URL | https://www.rebeccalennon.co.uk/ |
| Title | Scientific advisor to Christine Poulson to develop ideas for novel |
| Description | Novel " An air that kills" features the use of mosquitoes for murder mystery theme for a lab based plot. Advice was given on how mosquitoes are bred, tested for infection and resistance, and consultation on the scientific authenticity of scenarios discussed. |
| Type Of Art | Creative Writing |
| Year Produced | 2019 |
| Impact | Novel published by Lion Fiction worldwide in November 2019. Available from all good book stores and Amazon. currently in the top 1000 all time selling medical thrillers on Amazon |
| URL | http://www.christinepoulson.co.uk/ |
| Description | Anti-Vec |
| Amount | £94,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 01/2020 |
| Description | Antigen Discovery NIH SBIR Grant |
| Amount | $224,000 (USD) |
| Organisation | Antigen Discovery Inc |
| Sector | Private |
| Country | United States |
| Start | 03/2018 |
| End | 02/2019 |
| Description | Assessing the impact of epitope on the efficacy of engineered monoclonal antibody-based drugs against human malaria |
| Amount | £26,059 (GBP) |
| Funding ID | IAA2164 |
| Organisation | Liverpool School of Tropical Medicine |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2023 |
| End | 12/2024 |
| Description | BactiVac Catalyst Funding Project: Identification of correlates of protection against pneumococcal colonization |
| Amount | £55,000 (GBP) |
| Organisation | University of Birmingham |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 08/2019 |
| Description | BactiVac Pumppriming Grant |
| Amount | £50,000 (GBP) |
| Funding ID | MC_PC_17222 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 08/2019 |
| Description | Click-chemistry to enhance therapeutic efficacy and translational potential of the IgG-Fc |
| Amount | £37,018 (GBP) |
| Organisation | Centre for Excellence in Infectious Disease Research Innovations |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 05/2020 |
| Description | Enceph-IG - Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults: A randomised double-blind placebo-controlled trial |
| Amount | £2,731,532 (GBP) |
| Funding ID | NIHR EME Project 17/60/67 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2024 |
| Description | Exapnding Excellence in England 'Centre for Drugs and Diagnostics' |
| Amount | £9,843,478 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2024 |
| End | 07/2029 |
| Description | Exploiting glycosylation against COVID-19 |
| Amount | £185,675 (GBP) |
| Funding ID | BB/V017772/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2020 |
| End | 06/2022 |
| Description | HPLC Analysis of Insecticides for new product development |
| Amount | £94,014 (GBP) |
| Funding ID | MRA 26 Project Amendment 12 |
| Organisation | IVCC |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 12/2023 |
| Description | ICF - Evaluate the potential of AstraZeneca's sialic acid tag technology for treating influenza viruses with Fc-molecules |
| Amount | £228,299 (GBP) |
| Funding ID | MR/Y503459/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2025 |
| Description | IVCC |
| Amount | £56,100 (GBP) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 05/2018 |
| End | 12/2018 |
| Description | IVCC contract |
| Amount | £75,000 (GBP) |
| Organisation | IVCC |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 03/2019 |
| Description | IVCC project award |
| Amount | £18,000 (GBP) |
| Organisation | IVCC |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 07/2018 |
| Description | Institutional Partnership Awards 'LSTM translational enabler' |
| Amount | £300,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 03/2023 |
| Description | MRC CiC |
| Amount | £650,000 (GBP) |
| Funding ID | MC_PC_17167 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 09/2019 |
| Description | MRC CiC - AAV-vectored delivery of engineered monoclonal antibodies as a prophylactic strategy against bloodstage malaria |
| Amount | £38,574 (GBP) |
| Funding ID | not known |
| Organisation | Liverpool School of Tropical Medicine |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 02/2022 |
| Description | MRC P2D |
| Amount | £125,000 (GBP) |
| Funding ID | MC_PC_16078 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 06/2018 |
| Description | NIH-Small Business Innovation Research Grant |
| Amount | $300,000 (USD) |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 01/2018 |
| End | 01/2019 |
| Description | P2D |
| Amount | £64,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 12/2019 |
| Description | Preemptive discovery of insecticide cross-resistance mechanisms for next generation malaria control products |
| Amount | £769,618 (GBP) |
| Funding ID | MR/V001264/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 01/2025 |
| Description | Wellcome Trust Innovator Award |
| Amount | £484,578 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 02/2019 |
| Title | Assay for monitoring and evaluation of indoor residual spray operations |
| Description | Quality control of indoor residual spraying (IRS) is necessary to ensure that spray operators (SOs) deposit the correct concentration of insecticide on sprayed structures, while also confirming that spray records are not being falsified. A high performance liquid chromatography (HPLC) method has been developed to rapidly monitor insecticide deposition for quality assessment of spray operations |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Has been used by malaria control operations on Bioko Island, Nigeria to improve spray performance |
| URL | https://doi.org/10.1186/s12936-020-3118-y |
| Title | GM mosquitoes expressing specific P450s |
| Description | Generation of GM Anopheles Gambia mosquitoes over expressing specific insecticide metabolising P450s |
| Type Of Material | Model of mechanisms or symptoms - non-mammalian in vivo |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | Mosquitoes are being used for commercial testing of volatile compounds in a genetic background of high P450 metabolism. The work will inform policy on the use of volatile compounds for malaria control. |
| Title | Geneticaly modified mosquito line created overexpressing Glutathione S-Transferase |
| Description | We have created mosquito lines that overexpress a GST thought to be responsible for resistance to a number of insecticide classes. These can be tested against alternative novel and repurposed compounds to gauge the likelihood of resistance already in the field or that may develop rapidly against these compounds. |
| Type Of Material | Model of mechanisms or symptoms - non-mammalian in vivo |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | To date, the tool has shown that GST can give rise to resistance to diagnostic doses of DDT. This is the first time that a direct in vivo relationship between an insecticide and a GST has been documented |
| Title | High throughout HPLC method for bednet QC |
| Description | Long-lasting insecticide-treated nets (LLINs) play a crucial role in preventing malaria transmission. LLINs should remain effective for at least three years, even after repeated washings. Currently, monitoring insecticides in LLINs is cumbersome, costly, and requires specialized equipment and hazardous solvents. We have developed a simplified HPLC method to rapidly extract insecticides from bednets that makes it easier to analyse nets with high precision and accuracy, improving throughput and reducing labour, costs, and environmental impact. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | The assay is being used for QA of bednet batches for distribution in Africa. |
| URL | https://doi.org/10.1038/s41598-022-13768-z |
| Title | High throughput screen for anopheles |
| Description | Adapted software to analyse behaviour of Anopheles larvae |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | We have provided proof of principle screens of compounds and selected repurposed pest and agricultural insecticides to identify novel active compounds against mosquitoes |
| Description | Antigen Discovery Partnership |
| Organisation | Antigen Discovery Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | The collaboration with ADI aims to identify novel protein-based vaccine candidates against pneumonia using the proteome array from Antigen Discovery and samples derived from our Experimental Human Challenge model with Pneumococcus. Dr Solórzano-Gonzalez received a 2-week one-to-one training at ADI where she gained knowledge about their technology and how to analyse the data generated from that platform. We provided 300 serum and nasal wash samples, from the EHPC model to be analysed on their platform. |
| Collaborator Contribution | Antigen Discovery provided their panproteome pneumococcal microarray and contributed towards the second week of Carla's visit, in order to gain further knowledge of their platform. |
| Impact | In January 2018 we were granted together with ADI a NIH-Small Business Innovation Research Grant ($300,000) for analysing a total of 300 serum and nasal wash samples derived from our human model in ADI's platform. All the data has been analysed and a manuscript is in preparation. |
| Start Year | 2018 |
| Description | Collaborating with Abaxon Biologics |
| Organisation | Abaxon Biologics |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Discussion are on-going with licensing monomeric-Fc patents covering new therapies for neurology |
| Collaborator Contribution | Due diligence |
| Impact | None as yet |
| Start Year | 2018 |
| Description | Developing blockers of Zika infection |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration with Professor Alain Kohl |
| Collaborator Contribution | Will test our hypersialyaletd Fc fragments at controlling viruses |
| Impact | none yet |
| Start Year | 2019 |
| Description | Hypersialylated blockers of Zika virus (ZIKV) infectivity and neuropathology. |
| Organisation | University of Glasgow |
| Department | Institute of Infection, Immunity and Inflammation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are testing hypersialylated Fc molecules for controlling Zika mediated neurodegeneration |
| Collaborator Contribution | Provide virus models of neural degeneration |
| Impact | too early |
| Start Year | 2018 |
| Description | Identifying resistance liabilities to new insecticides in mosquitoes that transmit urban tropical diseases |
| Organisation | IVCC |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Supervised PhD project |
| Collaborator Contribution | Envu hosted PhD student and covered PhD student fees and research costs in Germany and involved in research development; IVCC covered UK research costs and involved in research development |
| Impact | Project has just begun, too early for outputs |
| Start Year | 2022 |
| Description | Molecular characterisation of insecticides and combination effects against mosquitoes |
| Organisation | Bayer |
| Country | Germany |
| Sector | Private |
| PI Contribution | Created and supervised PhD project |
| Collaborator Contribution | Bayer hosted PhD student and paid research costs in Germany and UK student fees, IVCC covered UK research costs |
| Impact | 4 publications - DOI's 10.1016/j.pestbp.2022.105051 10.1016/J.CRPVBD.2021.100041 https://doi.org/10.1016/j.ibmb.2022.103813 10.1016/j.pestbp.2023.105356 multidisciplinary - molecular biology, biochemistry and pharmacology of insecticide metabolism, |
| Start Year | 2018 |
| Description | Molecular characterisation of insecticides and combination effects against mosquitoes |
| Organisation | IVCC |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Created and supervised PhD project |
| Collaborator Contribution | Bayer hosted PhD student and paid research costs in Germany and UK student fees, IVCC covered UK research costs |
| Impact | 4 publications - DOI's 10.1016/j.pestbp.2022.105051 10.1016/J.CRPVBD.2021.100041 https://doi.org/10.1016/j.ibmb.2022.103813 10.1016/j.pestbp.2023.105356 multidisciplinary - molecular biology, biochemistry and pharmacology of insecticide metabolism, |
| Start Year | 2018 |
| Description | Prospective liability of novel and repurposed compounds to metabolic resistance in An. gambiae (3) |
| Organisation | CE Bioscience Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We lead a research project examining the genetics of insecticide resistance in msoquitoes. We perform functional genetic modification to examine the role of different gene families in resistacne phenotypes, in order to develop methods and compounds to overcome this resistance. |
| Collaborator Contribution | The partners have developed a high throughput rapid screen of larval susceptibility to compounds based on image analysis of multiwell plates of larvae to monitor behaviour and death. |
| Impact | Successful application for an MRC iCASE Studentship to develop the system further. The collaboration is multidisciplinary involving biological, physiochemcal and computational analysis to provide both qualitative and quantitative analysis. |
| Start Year | 2017 |
| Description | collaboration with CeBiosciences |
| Organisation | CE Bioscience Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Joint project to examine high throughput larval assays for mosquitos. PhD student undertook 10 visits to use facilities at Cebiosciences. |
| Collaborator Contribution | Cebiosciences provided expertise in hardware usage and access to IP regulated software for analysis |
| Impact | Publications: Nature: The screen of repurposed chemicals is included in a Nature article (14/11/18) with co-authors from both partners. 'Improved reference genome of Aedes aegypti informs arbovirus vector control'.10.1038/s41586-018-0692-z Draft Manuscript in prep for PLOS NTD: Automated phenotyping of mosquito larvae enables high-throughput screening for novel larvicides and smartphone-based detection of larval insecticide resistance Presentations: 3 presentations and poster at Pyrethrum conference Cambridge Sept 3- 5 2018 Gareth Lycett: invited talk - Developing a toolkit for genetic analysis and control of malarial vectors David Sattelle: invited talk - Automated phenotyping for larvicidal screening and detection of resistance Beth Poulton: turbo talk and poster - Rapid, automated insecticide resistance analysis in mosquito larvae Awards A new MRC P2D project between LSTM (vector/parasitology groups )and CeBiosciences has been awarded: Examining snake venom peptides as novel reagents to address the burgeoning global threat to health and agriculture of pesticide-resistance Amount Awarded: £64,085.33 |
| Start Year | 2017 |
| Title | CHIMERIC FC RECEPTOR BINDING PROTEINS AND USES THEREOF |
| Description | The present invention relates to chimeric proteins, to compositions comprising such proteins and to the medical uses of such proteins and compositions. In particular the proteins or compositions of the invention may be used in the prevention or treatment of autoimmune diseases or inflammatory diseases, or for the prevention or treatment of diseases mediated through binding of sialic acid dependent receptors, or as vaccines or as anti-cancer agents. One aspect of the invention relates to a chimeric Fc receptor binding protein which comprises two chimeric polypeptide chains, wherein each chimeric polypeptide chain comprises an immunoglobulin G heavy chain constant region, a tailpiece region and a hinge region, wherein the amino acid sequence of each polypeptide chain possess a sugar moiety at or close to the N-terminus and a sugar moiety at or close to the C- terminus, and their use in the treatment or prevention of a disease mediated by a pathogen that relies on sialic acid receptors interactions. |
| IP Reference | WO2019175605 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Commercial In Confidence |
| Impact | Currently in negotiations for licensing |
| Title | FUSION PROTEIN COMPRISING MULTIPLE HINGE SEQUENCES |
| Description | The invention relates to fusion polypeptides derived from IgG. The fusion polypeptides comprise a domain derived from an immunoglobulin heavy chain constant region; and a plurality of hinge regions derived from IgG hinge sequences. The invention also relates to nucleic acids encoding the fusion polypeptides, and to proteins comprising two fusion polypeptides of the invention. Also provided are a pharmaceutical composition comprising a fusion polypeptide and/or protein of the invention, and medical uses of the polypeptides, proteins, or compositions. |
| IP Reference | WO2019175606 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | New approaches to deliver antigens that don't interfere with receptor binding |
| Title | HexaGard UK00003018151 |
| Description | A drug name for hexameric Fc fusion |
| IP Reference | |
| Protection | Trade Mark |
| Year Protection Granted | 2013 |
| Licensed | Yes |
| Impact | This patent has been licensed to UCB Pharma for further development and they are talking it into national phase. We now collaborate with UCB Pharma |
| Title | IMMUNOMODULATORY PROTEINS |
| Description | A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject. |
| IP Reference | US2018362600 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | To UCB pharma from 2015-2017. To be licensed to CSL Behring from mid 2019 |
| Title | IMMUNOMODULATORY PROTEINS |
| Description | A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject. |
| IP Reference | WO2014060712 |
| Protection | Patent granted |
| Year Protection Granted | 2014 |
| Licensed | Yes |
| Impact | Non-exclusively licensed to UCB Pharma Patent has now been granted unopposed in Europe |
| Title | MONOMERIC PROTEINS AND USES THEREOF |
| Description | Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and/or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use. |
| IP Reference | WO2017191439 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | Publication see Journal of Immunology 2018 |
| Title | Murine antibodies |
| Description | A mouse fusion protein comprising two chimeric polypeptide chains each comprising two murine IgG heavy chain chains having an immunoglobulin tailpiece from, or derived from, a non-native immunoglobulin and wherein the amino acid sequence of each of the IgG heavy chain constant regions comprises an amino acid modification (e.g. M84C) which promotes the multimerisation or polymerisation of the fusion protein. Preferably the tailpiece is human and is derived from IgM or IgA and has a substitution or deletion at residue C17. Preferably, each chimeric chain comprises one or more murine hinge regions and a targeting moiety such as an ntigen binding region, small molecule or nucleic acid. The invention further relates to the uses of the fusion protein to detect a target molecule in a sample, preferably as a means for diagnosis such as blood group haemagglutination. |
| IP Reference | GB2572008 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | none as yet |
| Title | POLYMERIC PROTEINS AND USES THEREOF |
| Description | Provided are polymeric proteins that comprise two or more polypeptide monomer units, each monomer unit comprising two chimeric protein chains. Each chimeric polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions,wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit. Each chimeric protein chain also comprises a modified immunoglobulin M tailpiece region, wherein the amino acid sequence of each chimeric polypeptide monomer comprises an alteration of the primary structure as compared to the native sequences from which the immunoglobulin G heavy chain constant region or immunoglobulin M tailpiece region are derived, and the alteration changes the number of glycosylation sites in a manner that promotes polymerisation. This promotion of polymerisation may lead to the generation of tetrameric, hexameric, and even dodecameric forms of the proteins. The proteins are suitable formedical uses,such as in the prevention or treatment of autoimmune diseases such as idiopathic thrombocytopenia. Also provided are methods of treatment using the polymeric proteins, and pharmaceutical compositions comprising the polymeric proteins. |
| IP Reference | WO2016009232 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | N/A |
| Description | Conference British Association for Lung Research (BALR) 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | British Association for Lung Research (BALR) 2021 Conference at the University of Exeter on 24 and 25 June 2021 (Katerina attended on Zoom). Katerina presented a poster entitled A novel multiplex assay using Luminex xMAP technology to screen for pneumococcal vaccine candidates. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Conference Talk |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Daniela ferreira presented about how Pneumococcal carriage dampens immune response to repiratory virus. This talk was part of a conference aiming to discuss the "evolving understanding of the causes of pneumonia in adults" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Elimination 8 workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Project was presented as part of a state of the art training in current entomological methods. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://malariaelimination8.org |
| Description | Europneumo Liverpool 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Speaker at Europneumo Liverpool 2022 . Resulted in increased collaboration and development of international scientific partnerships. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Glycan engineering for vaccines presented at Pirbright |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | BSI frontiers in human immunology antibody discovery |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.immunology.org/events/frontiers-in-human-and-veterinary-antibody-discovery |
| Description | HIC VAC meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Spoke at this conference. Resulted in increased collaboration and development of scientific partnerships. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Hic vac annual meeting 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Speaker at Hic Vav 2022. Resulted in increased collaboration and development of international scientific partnerships. |
| Year(s) Of Engagement Activity | 2022 |
| Description | ISPPD Society Toronto 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Speaker at ISPDD Toronto 2022. Resulted in increased collaboration and development of international scientific partnerships. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Industry visit |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Visit to LSTM laboratories by a group of 15 scientists, business people and funders involved in the development of new products to control mosquito vectors of disease. Include small and large companies including Mitsui, BASF, Vestergaard, Syngenta, BMGF. Discussions revolved around the application of research on new diagnostic insecticide resistance probes, transgenic mosquitoes, analytical methods for quality assurance of new products, future direction of vector control reseach |
| Year(s) Of Engagement Activity | 2023 |
| Description | International Conference |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Invited Speaker 19th May 2018. 11th International Congress on Autoimmunity. Lisbon. Invited by Fabian Kasermann CSL Behring. N-terminal hinge glycosylation brings novel receptor binding properties to human IgG1-Fc multimers and monomers. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://autoimmunity.kenes.com/2018#.W8CDcS2ZNBy |
| Description | Interview with Proteogenix |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Spoke and wrote about my thoughts on antibodies and their role in controlling Sars-CoV-2 |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.proteogenix.science/scientific-corner/antibody-production/interview-professor-richard-pl... |
| Description | Invited Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | 19th September 2018. IITM Perspectives Meeting: Biologics as Therapeutics. Invited by Profs. Chris Tang and Helen McShane. University of Oxford. N-terminal hinge glycosylation for novel receptor interactions of IgG Fc monomers and multimers . University of Oxford doctoral training programme. I provided the wisdom of my experience about translating research. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://iitmoxford.files.wordpress.com/2018/09/booklet_iitm_symposium-2018.pdf |
| Description | Invited Speaker: Mosquito Research - From Sensory Biology to Vector Control |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Workshop on using research into sensory biology for vector control |
| Year(s) Of Engagement Activity | 2019 |
| Description | MSD EMEAC Pneumo SASS - live session |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Industry and internal business partners attended this meeting to further collaboration and partnership, this engagement resulted in increased interest in the programme |
| Year(s) Of Engagement Activity | 2021 |
| Description | Poster presentation and participation in IVCC Stakeholder meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Poster presentation and networking discussions with members of industry, policy-makers and field operatives involved in the production of new tools to control mosquitoes and malaria |
| Year(s) Of Engagement Activity | 2019 |
| Description | Presentation to the Wellcome Trust |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Presented my translational activity to the Wellcome Trust as part of a successful bid for Wellcome Trust Translational Partnership Funding |
| Year(s) Of Engagement Activity | 2019 |
| Description | Presented our work at British Society for Parasitology |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented talk "Glycan engineering of the IgG1-Fc for therapeutic and vaccine applications |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.lstmed.ac.uk/news-events/news/the-british-society-for-parasitology-autumn-symposium-in-l... |
| Description | Presented our work at the British Society for Immunology 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented our work at the BSI meeting held in Liverpool |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.bsicongress.com/bsi/frontend/reg/titem.csp?pageID=1399&eventID=2&eventID=2 |
| Description | School entrepreneur visit |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Award winning school children that had invented and trying to market novel approaches to disease control visited the dept to examine the transgenic mosquito colonies we have generated that feature in this award. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | My seminar on my Wellcome Trust research is available to view at: https://www.lstmed.ac.uk/news-events/seminars-and-lectures/engineering-the-igg1-fc-for-enhanced-therapeutic-applications-a |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.lstmed.ac.uk/news-events/seminars-and-lectures/engineering-the-igg1-fc-for-enhanced-ther... |
| Description | Webinar for Vellore Institute of Technology, India |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | The Webinar "Preemptive discovery of insecticide cross-resistance mechanisms for next generation malaria control products" was on the invitation of the VIT Centre for Nanobiotechnology as part of the VIT-CNBT International Webinar Series. The purpose was to present the latest research being done in my group in the area of mosquito control. Around 50 people attended and there were a number of questions and discussion around the use of chemicoproteomic approaches for mapping resistance mechanisms. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Work highlighted by Genetic Engineering & Biotechnology News |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Our Wellcome Trust funded work on influenza was highlighted |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.genengnews.com/news/influenza-drug-platform-could-yield-candidates-for-multiple-pathogen... |
| Description | Work highlighted in the journal Nature |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Our work was highlighted by Nature |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.nature.com/magazine-assets/d41586-019-02753-8/d41586-019-02753-8.pdf |
| Description | new anti-influenza drugs highlighted by Science Daily |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | https://www.sciencedaily.com/releases/2019/01/190125120114.htm |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.sciencedaily.com/releases/2019/01/190125120114.htm |
| Description | pyrethrum conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Gareth Lycett: invited talk - Developing a toolkit for genetic analysis and control of malarial vectors |
| Year(s) Of Engagement Activity | 2018 |
| Description | turbo talk and poster international conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | PhD student on project Beth Poulton: turbo talk and poster - Rapid, automated insecticide resistance analysis in mosquito larvae |
| Year(s) Of Engagement Activity | 2018 |
| Description | visit by Finance staff London School of Tropical Medicine and Hygiene |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Visit by the LSTMH finance dept to provide them with an overview of the research taking place in my lab and vector group to generate cross institute interest in our respective research priorities |
| Year(s) Of Engagement Activity | 2019 |
| Description | visit by Research England |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | A visit to the insectaries to discuss the work being done in the dept under funding from UKRI, and wider issues of research policy |
| Year(s) Of Engagement Activity | 2018 |